VistaGen Therapeutics Inc. VSTA Archives

WednesdayDec 19, 2012 3:23 pm

Excitement at VistaGen Therapeutics (VSTA) Continues to Build

lot of great things have been happening with VistaGen Therapeutics recently. VistaGen is a California-based biotechnology company actively applying its proprietary human pluripotent stem cell technology to launch a new era of drug rescue, predictive heart and liver toxicology, and drug metabolism screening. VistaGen’s unique stem cell technology-based Human Clinical Trials in a Test Tube™ platform currently involves controlled differentiation (development) of pluripotent stem cells into mature, functional human heart and liver cells that can then be used to predict early in development whether a drug candidate has potential toxicity problems. Determination of potential heart and liver toxicity early on…

MondayDec 03, 2012 7:38 am

VistaGen Therapeutics, Inc. (VSTA) Joins Centre for Commercialization of Regenerative Medicine (CCRM) Consortium

VistaGen Therapeutics, a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, today announced its membership in the Toronto-based Centre for Commercialization of Regenerative Medicine’s (CCRM) Industry Consortium. “VistaGen’s membership reflects our strong association with CCRM and its core programs and objectives, both directly and through our strategic relationships with Dr. Gordon Keller and the University Health Network (UHN). Our long-term sponsored research agreement with Dr. Keller, UHN and UHN’s McEwen Centre for Regenerative Medicine offers both a solid foundation and unique opportunities for expanding the commercial applications of our Human Clinical Trials in…

WednesdayNov 21, 2012 6:02 pm

VistaGen Therapeutics (VSTA) Focused on Preventing Some Very Costly Surprises

Recently, when Bristol-Myers Squibb was forced to suspend testing of its pill for hepatitis C because one of the patients suffered heart failure, it was a major blow to the pharmaceutical giant. Bristol had spent more than a billion dollars in their search for a hepatitis C treatment, and they thought they had it with a nucleotide from an earlier acquired company called Inhibitex. The potential market is enormous for an effective remedy that is easier to administer than current hepatitis C treatments, with possible sales estimated to be well over a billion dollars. Bristol had paid $2.5 billion in…

TuesdayNov 13, 2012 6:50 pm

VistaGen Therapeutics, Inc. (VSTA) Announces Enhancement of Predictive Liver Toxicology and Drug Metabolism Bioassay System

VistaGen Therapeutics, a biotechnology company applying stem cell technology for drug rescue, predictive toxicology, and drug metabolism screening, today announced a significant advance in its development of LiverSafe 3D™, a human liver cell-based bioassay system designed to predict liver toxicity and drug metabolism issues in connection with the company’s drug rescue activities. Shawn K. Singh, VistaGen’s Chief Executive Officer, stated, “As we have done with CardioSafe 3D™, our stem cell-based bioassay system for predictive heart toxicity screening and drug rescue, we are developing LiverSafe 3D™ to change the game in drug development — to generate clinically predictive liver toxicology and…

MondayNov 12, 2012 6:53 pm

VistaGen Therapeutics, Inc. (VSTA) Taps the Turnaround

The idea of a turnaround is often associated with dysfunctional companies being purchased by outsiders or otherwise given new management, and then being transformed with a change in product, structure, or philosophy, providing a fresh and profitable direction for what had been a losing asset. If coming from the outside, the process can be extremely lucrative, allowing a purchase or major stake at bargain basement prices, and then rapidly growing that investment through the application of proven principles. Individuals and companies who have taught themselves how to identify and resolve corporate weaknesses stand to profit handsomely once they have the…

WednesdayNov 07, 2012 10:47 am

VistaGen Therapeutics, Inc. (VSTA) Presents Heart Tissue Engineering Progress at American Heart Association 2012 Scientific Sessions

VistaGen Therapeutics, a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, today announced that results of their collaboration with Duke University were presented this week at the American Heart Association 2012 Scientific Sessions in Los Angeles. The presentation, entitled “Human embryonic stem cell-derived cardiac tissue patch with advanced structure and function,” illuminated the important synergistic interactions of VistaGen’s stem cell-derived human cardiomyocytes (heart cells) and Duke’s tissue engineering and analytical technologies. The research, which expands the scope of VistaGen’s drug rescue capabilities focused on heart toxicology, was led at Duke by Dr. Nenad…

Site Search

Company Search

Tag: VistaGen Therapeutics Inc. VSTA

Excitement at VistaGen Therapeutics (VSTA) Continues to Build

VistaGen Therapeutics, Inc. (VSTA) Joins Centre for Commercialization of Regenerative Medicine (CCRM) Consortium

VistaGen Therapeutics (VSTA) Focused on Preventing Some Very Costly Surprises

VistaGen Therapeutics, Inc. (VSTA) Announces Enhancement of Predictive Liver Toxicology and Drug Metabolism Bioassay System

VistaGen Therapeutics, Inc. (VSTA) Taps the Turnaround

VistaGen Therapeutics, Inc. (VSTA) Presents Heart Tissue Engineering Progress at American Heart Association 2012 Scientific Sessions

Market Basics

Newsletter Publishers

Public Companies